Antibody Containment Genotoxicity Marketing 
The Pharma Data
MARCH 25, 2021
The validation of our EU marketing application is an important step toward addressing the significant unmet medical need for people with metastatic triple-negative breast cancer.”. including final safety information for prescribers) will be assessed as part of ongoing and future Marketing Authorization Applications.
The Pharma Data
APRIL 7, 2021
The European Medicines Agency has also validated a Marketing Authorization Application for Trodelvy in the European Union. TRODELVY contains a genotoxic component, SN-38, and targets rapidly dividing cells. All filings are based on data from the Phase 3 ASCENT study. Trodelvy Boxed Warning. The Trodelvy U.S. About Trodelvy.
Expert insights. Personalized for you.
52 
Let's personalize your content